Connecting People With Diabetes to Clinical Research That Matters

Review ongoing clinical trials, surveys, and research opportunities from trusted biotech and medical research partners.

Find us

Essex Junction, VT 0452, USA

Email us

ginger@diabetesnerd.com

,

First “Gene-Edited” Islet Cell Survives 12 Weeks in T1D Man

  • By Ginger Vieira
  • August 6, 2025
  • 329 Views

On August 6, 2025, researchers from Uppsala University in Sweden reported that gene-edited islet cells have survived for 12 weeks in a man with long-standing type 1 diabetes without any immunosuppression therapy.

This was the first in-human clinical trial using “hypoimmune” cells, testing their ability to avoid being attacked and rejected by the body’s immune system.

The hypoimmune cells were engineered using cells from a deceased donor, then edited with CRISPR technology. The recipient only received 7 percent of the full replacement dose, and therefore, continued daily insulin therapy to manage blood glucose levels.

This is exciting: hypoimmune cells are engineered to hide from the immune system without the need for immunosuppression therapy.

Will the cells continue to successfully produce insulin? We’ll see as the study continues!

Congrats to Uppsala for this groundbreaking progress!

Here’s the full report: https://bit.ly/3J2nuDX